LONDON (Alliance News) - The following UK shares received analyst recommendations Monday morning:
----------
FTSE 100
----------
BERENBERG CUTS SSE PRICE TARGET TO 1320 (1570) PENCE - 'HOLD'
----------
BERENBERG CUTS REED ELSEVIER TO 'HOLD' ('BUY') - TARGET 930 (895) PENCE
----------
MERRILL LYNCH CUTS TESCO TO 'UNDERPERFORM' ('NEUTRAL')
----------
NOMURA RAISES BURBERRY PRICE TARGET TO 1650 (1630) PENCE - 'NEUTRAL'
----------
CREDIT SUISSE RAISES SHELL PRICE TARGET TO 2450 (2350) PENCE - 'OUTPERFORM'
----------
CITIGROUP RAISES WOLSELEY PRICE TARGET TO 3660 (3596) PENCE - 'BUY'
----------
EXANE BNP RAISES ASTRAZENECA PRICE TARGET TO 3500 (3200) PENCE - 'NEUTRAL'
----------
EXANE BNP RAISES SHIRE PRICE TARGET TO 3600 (3100) PENCE - 'OUTPERFORM'
----------
Jefferies Raises Next Price Target To 7,500p From 7,000p - Buy
----------
LIBERUM CUTS WPP PRICE TARGET TO 1280 (1600) PENCE - 'HOLD'
----------
BARCLAYS RAISES STANDARD LIFE PRICE TARGET TO 377 (349) PENCE - 'EQUAL WEIGHT'
----------
FTSE 250
----------
BARCLAYS RAISES MICRO FOCUS TO 'OVERWEIGHT' ('EQUAL WEIGHT')
----------
CITIGROUP CUTS BWIN.PARTY TO 'SELL' ('NEUTRAL') - TARGET 95 (125) PENCE
----------
UBS RAISES BALFOUR BEATTY PRICE TARGET TO 260 (250) PENCE - 'SELL'
----------
UBS CUTS OXFORD INSTRUMENTS PRICE TARGET TO 1600 (1750) PENCE - 'BUY'
----------
CITIGROUP RAISES HIKMA PHARMACEUTICALS PRICE TARGET TO 1800 (1700) P. - 'BUY'
----------
JPMORGAN RAISES BODYCOTE PRICE TARGET TO 655 (540) PENCE - 'UNDERWEIGHT'
----------
JPMORGAN RAISES RPS GROUP PRICE TARGET TO 351 (341) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS REGUS PLC PRICE TARGET TO 174 (177) PENCE - 'UNDERWEIGHT'
----------
BERNSTEIN RAISES HOME RETAIL TO 'MARKET-PERFORM' ('UNDERPERFORM.') - PT 190 (140) PENCE.
----------
BARCLAYS INITIATES COMPUTACENTER WITH 'UNDERWEIGHT' - TARGET 600 PENCE
----------
JEFFERIES RAISES COMPUTACENTER PRICE TARGET TO 720 (470) PENCE - 'HOLD'
----------
MAIN MARKET AND AIM
----------
PANMURE RAISES HELLENIC CARRIERS PRICE TARGET TO 60 (50) PENCE - 'BUY'
----------
Copyright 2014 Alliance News Limited. All Rights Reserved.
Hikma adjusts expectations amid injectables challenges
(Sharecast News) - Hikma Pharmaceuticals reported solid global growth in its injectables business on Thursday, with strong customer demand for its product portfolio in North America, although some challenges meant it expected revenue and operating margin growth at the lower end of guidance.
Read more